Abstract: Provided are antibodies that target the cellular efflux pump ABCC4. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCC4 expression in cells, e.g., tumor cells, level of ABCC4 expression, and/or inhibiting ABCC4 function are also disclosed. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCC4 antibody disclosed herein.

Abstract: Provided are antibodies that target the cellular efflux pump ABCC1. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCC1 expression in cells, e.g., tumor cells, Level of ABCC1 expression, and/or inhibiting ABCC1 function are also disclosed. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCC1 antibody disclosed herein. The subject antibody may be a bispecific antibody. The bispecific antibody may bind to ABCC1 and a tumor associated antigen (TAA).

Abstract: Provided are antibodies that target the cellular efflux pump ABCG2. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCG2 expression in cells, e.g., tumor cells, level of ABCG2 expression, and/or inhibiting ABCG2 function are also disclosed. In addition, multi-specific antibodies that bind to ABCG2 and a polypeptide expressed on surface of a cancer cell are provided. The polypeptide may be the efflux pump MDR1 or a cancer-associated antigen. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCG2 antibody as disclosed herein or a multi-specific antibody that targets both ABCG2 and a cancer-associated antigen or MDR1.

Abstract: Provided are antibodies that target the cellular efflux pump MDR1. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of MDR1 expression in cells, e.g., tumor cells, level of MDR1 expression, and/or inhibiting MDR1 function are also disclosed. In addition, multi-specific antibodies that bind to MDR1 and a tumor associated antigen are provided. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-MDR1 antibody as disclosed herein or a multi-specific antibody that targets both MDR1 and a tumorassociated antigen.

Abstract: Provided are multi-specific antibodies that target both the cellular efflux pump ABCG2 and a cancer-associated antigen as well as pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such multi-specific antibodies. Methods of treating a subject for a cancer that include administering to the subject a multi-specific antibody that targets both a cellular efflux pump and a cancer-associated antigen are also provided. Provided as well are methods of generating the described multi-specific antibodies and reagents related thereto, including genetically modified cell lines useful in the subject methods and methods of making such genetically modified cell lines.

Abstract: Provided are multi-specific antibodies that target both a cellular efflux pump and a cancer-associated antigen as well as pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such multi-specific antibodies. Methods of treating a subject for a cancer that include administering to the subject a multi-specific antibody that targets both a cellular efflux pump and a cancer-associated antigen are also provided. Provided as well are methods of generating the described multi-specific antibodies and reagents related thereto, including genetically modified cell lines useful in the subject methods and methods of making such genetically modified cell lines.

Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.

Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.

Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.

Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.